Mechanisms of aspirin resistance

Pharmacology and Therapeutics

Volumn 141, Issue 1, 2014, Pages 69-78

  Floyd, Christopher N ^a   Ferro, Albert ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Aspirin; Cardiovascular; Platelet; Resistance; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2C19; DICLOFENAC; DIPYRIDAMOLE; GLYCOPROTEIN IIIA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 4; OMEPRAZOLE; PROSTAGLANDIN E2; PROSTAGLANDIN H2; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR STIMULATING AGENT; TICLOPIDINE; BETA3 INTEGRIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ASPIRIN RESISTANCE; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR MORTALITY; CELL INTERACTION; CORONARY ARTERY BYPASS GRAFT; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG METABOLISM; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; ENZYME SYNTHESIS; FIRST PASS EFFECT; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL TRACT; HEART INFARCTION; HUMAN; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LONG TERM CARE; LOW DRUG DOSE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHARMACOKINETICS; PORTAL VEIN BLOOD; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; STOMACH ABSORPTION; STOMACH PH; SYSTEMIC CIRCULATION; TACHYPHYLAXIS; THROMBOCYTE AGGREGATION; THROMBOCYTE LIFESPAN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG INTERACTION; DRUG RESISTANCE; METABOLISM; THROMBOCYTE; THROMBOEMBOLISM; TREATMENT FAILURE;

ASPIRIN; BLOOD PLATELETS; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; DRUG RESISTANCE; HUMANS; INTEGRIN BETA3; MEDICATION ADHERENCE; TACHYPHYLAXIS; THROMBOEMBOLISM; THROMBOXANE A2; TREATMENT FAILURE;

EID: 84890560949     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.08.005     Document Type: Review

References (141)

1. N.S. Abraham, M.A. Hlatky, E.M. Antman, D.L. Bhatt, D.J. Bjorkman, and C.B. Clark ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents J Am Coll Cardiol 56 2010 2051 2066
2. A.B. Adamopoulos, G.N. Sakizlis, E.G. Nasothimiou, I. Anastasopoulou, E. Anastasakou, and P. Kotsi Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study J Cardiovasc Pharmacol 54 2009 163 168
3. G.I. Adebayo, J. Williams, and S. Healy Aspirin esterase activity - Evidence for skewed distribution in healthy volunteers Eur J Intern Med 18 2007 299 303
4. B. Aktas, A. Utz, P. Hoenig-Liedl, U. Walter, and J. Geiger Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies Stroke 34 2003 764 769
5. J.H. Alexander, R.A. Harrington, R.H. Tuttle, L.G. Berdan, A.M. Lincoff, and J.W. Deckers Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: receptor suppression using integrilin therapy Am J Cardiol 83 1999 1147 1151
6. T. Andersson, D. Morrison, P. Nagy, J. Pisupati, J. Schettler, and T.D. Warner Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers Am J Cardiovasc Drugs 12 2012 217 224
7. K. Anger, J. Kempfert, M. Kostelka, F.W. Mohr, and S. Dhein Platelet hyporesponsiveness to acetylsalicylic acid can be transferred by plasma in humans Pharmacology 85 2010 241 247
8. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
9. 2 J Thromb Haemost 6 2008 1933 1943
10. C. Baigent, L. Blackwell, R. Collins, J. Emberson, J. Godwin, and R. Peto Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
11. O. Belton, D. Byrne, D. Kearney, A. Leahy, and D.J. Fitzgerald Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis Circulation 102 2000 840 845
12. D.L. Bhatt, B.L. Cryer, C.F. Contant, M. Cohen, A. Lanas, and T.J. Schnitzer Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 363 2010 1909 1917
13. D.L. Bhatt, and E.J. Topol Scientific and therapeutic advances in antiplatelet therapy Nat Rev Drug Discov 2 2003 15 28
14. G.G. Biondi-Zoccai, M. Lotrionte, P. Agostoni, A. Abbate, M. Fusaro, and F. Burzotta A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease Eur Heart J 27 2006 2667 2674
15. G.A. Bonaterra, W. Hildebrandt, A. Bodens, R. Sauer, K.A. Dugi, and H.P. Deigner Increased cyclooxygenase-2 expression in peripheral blood mononuclear cells of smokers and hyperlipidemic subjects Free Radic Biol Med 38 2005 235 242
16. J. Builder, K. Landecker, D. Whitecross, and D.W. Piper Aspirin esterase of gastric mucosal origin Gastroenterology 73 1977 15 18
17. D. Capodanno, A. Patel, K. Dharmashankar, J.L. Ferreiro, M. Ueno, and M. Kodali Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease Circ Cardiovasc Interv 4 2011 180 187
18. 2 metabolites in humans Thromb Res 47 1987 647 656
19. F. Catella-Lawson, M.P. Reilly, S.C. Kapoor, A.J. Cucchiara, S. DeMarco, and B. Tournier Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J Med 345 2001 1809 1817
20. T. Chakroun, F. Addad, S. Yacoub, F. Abderrezak, G.T. Gerotziafas, and S. Abdelkafi The cyclooxygenase-1 C50T polymorphism is not associated with aspirin responsiveness status in stable coronary artery disease in Tunisian patients Genet Test Mol Biomarkers 15 2011 513 516
21. N. Clappers, M.G. van Oijen, S. Sundaresan, M.A. Brouwer, R.H. Te Morsche, and W. Keuper The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid Thromb Haemost 100 2008 70 75
22. A.J. Claxton, J. Cramer, and C. Pierce A systematic review of the associations between dose regimens and medication compliance Clin Ther 23 2001 1296 1310
23. J.P. Collet, T. Cuisset, G. Range, G. Cayla, S. Elhadad, and C. Pouillot Bedside monitoring to adjust antiplatelet therapy for coronary stenting N Engl J Med 367 2012 2100 2109
24. P.B. Costello, and F.A. Green Aspirin survival in human blood modulated by the concentration of erythrocytes Arthritis Rheum 25 1982 550 555
25. D. Cox, A.O. Maree, M. Dooley, R. Conroy, M.F. Byrne, and D.J. Fitzgerald Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers Stroke 37 2006 2153 2158
26. B. Cryer, and M. Feldman Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans Gastroenterology 117 1999 17 25
27. G.L. Dale Platelet kinetics Curr Opin Hematol 4 1997 330 334
28. L.M. Demers, R.E. Budin, and B.S. Shaikh The effects of aspirin on megakaryocyte prostaglandin production Proc Soc Exp Biol Med 163 1980 24 29
29. J.G. Dillinger, A. Drissa, G. Sideris, C. Bal dit Sollier, S. Voicu, and S. Manzo Silberman Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease Am Heart J 164 2012 (600-606 e601)
30. H. Dreser Pharmakologisches uber Aspirin (Acetylsalicylsaure) Pflugers Arch 1899 306 318
31. J.W. Eikelboom, G.J. Hankey, J. Thom, D.L. Bhatt, P.G. Steg, and G. Montalescot Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk Circulation 118 2008 1705 1712
32. J.W. Eikelboom, J. Hirsh, J.I. Weitz, M. Johnston, Q. Yi, and S. Yusuf Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events Circulation 105 2002 1650 1655
33. V. Evangelista, S. Manarini, A. Di Santo, M.L. Capone, E. Ricciotti, and L. Di Francesco De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin Circ Res 98 2006 593 595
34. M.E. Farkouh, H. Kirshner, R.A. Harrington, S. Ruland, F.W. Verheugt, and T.J. Schnitzer Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial Lancet 364 2004 675 684
35. S.H. Ferreira, S. Moncada, and J.R. Vane Indomethacin and aspirin abolish prostaglandin release from the spleen Nat New Biol 231 1971 237 239
36. L.M. Fischer, R.G. Schlienger, C.M. Matter, H. Jick, and C.R. Meier Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction Pharmacotherapy 25 2005 503 510
37. 2 as an amplifying signal for other agonists Am J Cardiol 68 1991 11B 15B
38. G.A. FitzGerald, J.A. Oates, J. Hawiger, R.L. Maas, L.J. Roberts II, and J.A. Lawson Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man J Clin Invest 71 1983 676 688
39. E. Flescher, R. Rotem, P. Kwon, J. Azare, I. Jaspers, and D. Cohen Aspirin enhances multidrug resistance gene 1 expression in human Molt-4T lymphoma cells Anticancer Res 20 2000 4441 4444
40. C.N. Floyd, and A. Ferro The platelet fibrinogen receptor: from megakaryocyte to the mortuary J R Soc Med Cardiovasc Dis 1 2012
41. C.N. Floyd, G. Passacquale, and A. Ferro Comparative pharmacokinetics and pharmacodynamics of platelet ADP receptor antagonists and their clinical implications Clin Pharmacokinet 51 2012 429 442
42. L.A. Garcia Rodriguez, S. Hernandez-Diaz, and F.J. de Abajo Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies Br J Clin Pharmacol 52 2001 563 571
43. L.A. Garcia Rodriguez, C. Varas-Lorenzo, A. Maguire, and A. Gonzalez-Perez Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population Circulation 109 2004 3000 3006
44. M.N. Giraud, S.K. Sanduja, T.B. Felder, P.A. Illich, E.J. Dial, and L.M. Lichtenberger Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats Aliment Pharmacol Ther 11 1997 899 906
45. T. Goodman, A. Ferro, and P. Sharma Pharmacogenetics of aspirin resistance: a comprehensive systematic review Br J Clin Pharmacol 66 2008 222 232
46. A.M. Gori, R. Marcucci, A. Migliorini, R. Valenti, G. Moschi, and R. Paniccia Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents J Am Coll Cardiol 52 2008 734 739
47. P. Gresner, M. Dolnik, I. Waczulikova, M. Bryszewska, L. Sikurova, and C. Watala Increased blood plasma hydrolysis of acetylsalicylic acid in type 2 diabetic patients: a role of plasma esterases Biochim Biophys Acta 1760 2006 207 215
48. T. Grosser, S. Fries, J.A. Lawson, S.C. Kapoor, G.R. Grant, and G.A. Fitzgerald Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin Circulation 2012
49. E.L. Grove, A.M. Hvas, S.B. Mortensen, S.B. Larsen, and S.D. Kristensen Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease J Thromb Haemost 9 2011 185 191
50. P.A. Gurbel, D. Erlinge, E.M. Ohman, B. Neely, M. Neely, and S.G. Goodman Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy J Am Med Assoc 308 2012 1785 1794
51. M. Hamberg, J. Svensson, and B. Samuelsson Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides Proc Natl Acad Sci U S A 72 1975 2994 2998
52. G.J. Hankey, and J.W. Eikelboom Aspirin resistance Lancet 367 2006 606 617
53. P.A. Harris, and S. Riegelman Influence of the route of administration on the area under the plasma concentration-time curve J Pharm Sci 58 1969 71 75
54. P. Harrison Assessment of platelet function in the laboratory Hamostaseologie 29 2009 25 31
55. J. Hart, C.J. Hawkey, A. Lanas, J. Naesdal, N.J. Talley, and A.B. Thomson Predictors of gastroduodenal erosions in patients taking low-dose aspirin Aliment Pharmacol Ther 31 2010 143 149
56. C.M. Helgason, K.M. Bolin, J.A. Hoff, S.R. Winkler, A. Mangat, and K.L. Tortorice Development of aspirin resistance in persons with previous ischemic stroke Stroke 25 1994 2331 2336
57. C.H. Hennekens, K. Schror, S. Weisman, and G.A. FitzGerald Terms and conditions: semantic complexity and aspirin resistance Circulation 110 2004 1706 1708
58. T. Hla, and K. Neilson Human cyclooxygenase-2 cDNA Proc Natl Acad Sci U S A 89 1992 7384 7388
59. P.M. Ho, J.A. Spertus, F.A. Masoudi, K.J. Reid, E.D. Peterson, and D.J. Magid Impact of medication therapy discontinuation on mortality after myocardial infarction Arch Intern Med 166 2006 1842 1847
60. M. Hofer, M. Pospisil, Z. Hoferova, L. Weiterova, and D. Komurkova Stimulatory action of cyclooxygenase inhibitors on hematopoiesis: a review Molecules 17 2012 5615 5625
61. T. Hohlfeld, A. Saxena, and K. Schror High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs - pharmacological mechanisms and clinical relevance Thromb Haemost 109 2012
62. J.A. Hyde, J.A. Chinn, and T.R. Graham Platelets and cardiopulmonary bypass Perfusion 13 1998 389 407
63. P. Inarrea, F. Esteva, R. Cornudella, and A. Lanas Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man Scand J Gastroenterol 35 2000 242 246
64. ISIS-2 Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Lancet 2 1988 349 360
65. G. Jedlitschky, K. Tirschmann, L.E. Lubenow, H.K. Nieuwenhuis, J.W. Akkerman, and A. Greinacher The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage Blood 104 2004 3603 3610
66. J. Karha, V. Rajagopal, K. Kottke-Marchant, and D.L. Bhatt Lack of effect of enteric coating on aspirin-induced inhibition of platelet aggregation in healthy volunteers Am Heart J 151 5 May 2006 976.e7 976.e11
67. D. Kearney, A. Byrne, P. Crean, D. Cox, and D.J. Fitzgerald Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor J Am Coll Cardiol 43 2004 526 531
68. K. Kotani, R. Caccavello, R. Hermo, T. Yamada, N. Taniguchi, and A. Gugliucci Serum cholesterol concentration associated with aspirin esterase activity in older people: preliminary data Int J Med Sci 7 2010 90 93
69. K. Kotani, S. Kimura, T. Ebara, R. Caccavello, and A. Gugliucci Serum aspirin esterase is strongly associated with glucose and lipids in healthy subjects: different association patterns in subjects with type 2 diabetes mellitus Diabetol Metab Syndr 2 2010 50
70. T. Kurth, R.J. Glynn, A.M. Walker, K.A. Chan, J.E. Buring, and C.H. Hennekens Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs Circulation 108 2003 1191 1195
71. K.C. Lai, S.K. Lam, K.M. Chu, B.C. Wong, W.M. Hui, and W.H. Hu Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use N Engl J Med 346 2002 2033 2038
72. M. Lordkipanidze, C. Pharand, E. Schampaert, J. Turgeon, D.A. Palisaitis, and J.G. Diodati A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease Eur Heart J 28 2007 1702 1708
73. T.M. MacDonald, and L. Wei Effect of ibuprofen on cardioprotective effect of aspirin Lancet 361 2003 573 574
74. T.M. MacDonald, and L. Wei Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen? Basic Clin Pharmacol Toxicol 98 2006 275 280
75. 2 biosynthesis J Lipid Mediat 6 1993 321 332
76. A.J. Marcus, B.B. Weksler, E.A. Jaffe, and M.J. Broekman Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells J Clin Invest 66 1980 979 986
77. T. Mattiello, R. Guerriero, L.V. Lotti, E. Trifiro, M.P. Felli, and A. Barbarulo Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting J Am Coll Cardiol 58 2011 752 761
78. 2 and prostacyclin in cigarette smokers Circulation 112 2005 1024 1029
79. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, J.R. Walker, and T. Simon Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis Lancet 376 2010 1312 1319
80. J.A. Mitchell, P. Akarasereenont, C. Thiemermann, R.J. Flower, and J.R. Vane Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase Proc Natl Acad Sci U S A 90 1993 11693 11697
81. P.R. Montgomery, and D.S. Sitar Acetylsalicylic acid metabolites in blood and urine after plain and enteric-coated tablets Biopharm Drug Dispos 7 1986 21 25
82. 2: physiology/pathophysiology, cellular signal transduction and pharmacology Pharmacol Ther 118 2008 18 35
83. C.J. Needs, and P.M. Brooks Clinical pharmacokinetics of the salicylates Clin Pharmacokinet 10 1985 164 177
84. F.H. Ng, P. Tunggal, W.M. Chu, K.F. Lam, A. Li, and K. Chan Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction Am J Gastroenterol 107 2012 389 396
85. M. Niazi, T. Andersson, E. Naucler, M. Sundin, and J. Naesdal Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers Int J Clin Pharmacol Ther 47 2009 564 569
86. J. Nowak, J.J. Murray, J.A. Oates, and G.A. FitzGerald Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes Circulation 76 1987 6 14
87. 2 and platelet aggregation in man Eur J Clin Pharmacol 25 1983 313 317
88. B. Oosterhuis, and J.H. Jonkman Omeprazole: pharmacology, pharmacokinetics and interactions Digestion 44 Suppl. 1 1989 9 17
89. 2 synthase activity in platelet free human monocytes Biochim Biophys Acta 1215 1994 285 290
90. J.C. Otto, and W.L. Smith Prostaglandin endoperoxide synthases-1 and -2 J Lipid Mediat Cell Signal 12 1995 139 156
91. A.C. Papp, L. Crowe, L.C. Pettigrew, and K.K. Wu Production of eicosanoids by deendothelialized rabbit aorta: interaction between platelets and vascular wall in the synthesis of prostacyclin Thromb Res 42 1986 549 556
92. S. Pascale, G. Petrucci, A. Dragani, A. Habib, F. Zaccardi, and F. Pagliaccia Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target Blood 119 2012 3595 3603
93. T.N. Patel, and K.C. Goldberg Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction Arch Intern Med 164 2004 852 856
94. P. Patrignani, P. Filabozzi, and C. Patrono Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects J Clin Invest 69 1982 1366 1372
95. C. Patrono, G. Ciabattoni, F. Pugliese, A. Pierucci, I.A. Blair, and G.A. FitzGerald Estimated rate of thromboxane secretion into the circulation of normal humans J Clin Invest 77 1986 590 594
96. C. Patrono, L.A. Garcia Rodriguez, R. Landolfi, and C. Baigent Low-dose aspirin for the prevention of atherothrombosis N Engl J Med 353 2005 2373 2383
97. A.K. Pedersen, and G.A. FitzGerald Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase N Engl J Med 311 1984 1206 1211
98. 2 production in human monocytes: implications for the use of cyclooxygenase inhibitors J Immunol 165 2000 1605 1611
99. C. Pettinella, M. Romano, L. Stuppia, F. Santilli, R. Liani, and G. Davi Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin Thromb Haemost 101 2009 687 690
100. F.M. Pulcinelli, P. Pignatelli, A. Celestini, S. Riondino, P.P. Gazzaniga, and F. Violi Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients J Am Coll Cardiol 43 2004 979 984
101. F.M. Pulcinelli, and S. Riondino More on aspirin resistance: position paper of the Working Group on Aspirin Resistance. Proposal for a Laboratory Test Guiding Algorithm J Thromb Haemost 4 2006 485 487
102. G. Reid, P. Wielinga, N. Zelcer, I. van der Heijden, A. Kuil, and M. de Haas The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs Proc Natl Acad Sci U S A 100 2003 9244 9249
103. J.L. Richardson, R.A. Shivdasani, C. Boers, J.H. Hartwig, and J.E. Italiano Jr. Mechanisms of organelle transport and capture along proplatelets during platelet production Blood 106 2005 4066 4075
104. 2 production Thromb Res 122 2008 359 365
105. B. Rocca, P. Secchiero, G. Ciabattoni, F.O. Ranelletti, L. Catani, and L. Guidotti Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets Proc Natl Acad Sci U S A 99 2002 7634 7639
106. G.J. Roth, and P.W. Majerus The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein J Clin Invest 56 1975 624 632
107. G.J. Roth, N. Stanford, and P.W. Majerus Acetylation of prostaglandin synthase by aspirin Proc Natl Acad Sci U S A 72 1975 3073 3076
108. M. Rowland, S. Riegelman, P.A. Harris, and S.D. Sholkoff Absorption kinetics of aspirin in man following oral administration of an aqueous solution J Pharm Sci 61 1972 379 385
109. P. Roy, L. Bonello, R. Torguson, A. de Labriolle, G. Lemesle, and T.L. Slottow Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation Am J Cardiol 102 2008 1614 1617
110. F.G. Russel, J.B. Koenderink, and R. Masereeuw Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules Trends Pharmacol Sci 29 2008 200 207
111. J. Santopinto, E.P. Gurfinkel, V. Torres, E. Marcos, G.E. Bozovich, and B. Mautner Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin Am Heart J 141 2001 566 572
112. J.M. Scheiman, P.J. Devereaux, J. Herlitz, P.H. Katelaris, A. Lanas, and S. Veldhuyzen van Zanten Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON) Heart 97 2011 797 802
113. W.S. Schroeder, L. Ghobrial, and P.J. Gandhi Possible mechanisms of drug-induced aspirin and clopidogrel resistance J Thromb Thrombolysis 22 2006 139 150
114. J.D. Schuetz, M.C. Connelly, D. Sun, S.G. Paibir, P.M. Flynn, and R.V. Srinivas MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs Nat Med 5 1999 1048 1051
115. K.A. Schwartz, D.E. Schwartz, K. Ghosheh, M.J. Reeves, K. Barber, and A. DeFranco Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction Am J Cardiol 95 2005 973 975
116. S.R. Seshasai, S. Wijesuriya, R. Sivakumaran, S. Nethercott, S. Erqou, and N. Sattar Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials Arch Intern Med 172 2012 209 216
117. E. Shantsila, and G.Y. Lip 'Aspirin resistance' or treatment non-compliance: which is to blame for cardiovascular complications? J Transl Med 6 2008 47
118. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, and N. Meneveau Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
119. S. Simsek, N.M. Faber, P.M. Bleeker, A.B. Vlekke, E. Huiskes, and R. Goldschmeding Determination of human platelet antigen frequencies in the Dutch population by immunophenotyping and DNA (allele-specific restriction enzyme) analysis Blood 81 1993 835 840
120. J. Summerbell, C. Yelland, and K. Woodhouse The kinetics of plasma aspirin esterase in relation to old age and frailty Age Ageing 19 1990 128 130
121. J.J. Sung, J.Y. Lau, J.Y. Ching, J.C. Wu, Y.T. Lee, and P.W. Chiu Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial Ann Intern Med 152 2010 1 9
122. U.S. Tantry, K.P. Bliden, and P.A. Gurbel Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation J Am Coll Cardiol 46 2005 1705 1709
123. D. Taubert, N. von Beckerath, G. Grimberg, A. Lazar, N. Jung, and T. Goeser Impact of P-glycoprotein on clopidogrel absorption Clin Pharmacol Ther 80 2006 486 501
124. UniProt Consortium Prostaglandin G/H synthase 1 UniProtKB Protein Knowledgebase 2012
125. E.C. van Pampus, P.C. Huijgens, A. Zevenbergen, H. Twaalfhoven, G.J. van Kamp, and M.M. Langenhuijsen Influence of aspirin on human megakaryocyte prostaglandin synthesis Eur J Haematol 50 1993 264 268
126. J.R. Vane Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nat New Biol 231 1971 232 235
127. J.R. Vane, Y.S. Bakhle, and R.M. Botting Cyclooxygenases 1 and 2 Annu Rev Pharmacol Toxicol 38 1998 97 120
128. K.W. von Pape, G. Strupp, T. Bonzel, and J. Bohner Effect of compliance and dosage adaptation of long term aspirin on platelet function with PFA-100 in patients after myocardial infarction Thromb Haemost 94 2005 889 891
129. A.A. Weber, B. Przytulski, A. Schanz, T. Hohlfeld, and K. Schror Towards a definition of aspirin resistance: a typological approach Platelets 13 2002 37 40
130. E.J. Weiss, P.F. Bray, M. Tayback, S.P. Schulman, T.S. Kickler, and L.C. Becker A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis N Engl J Med 334 1996 1090 1094
131. A.S. Weyrich, M.M. Denis, H. Schwertz, N.D. Tolley, J. Foulks, and E. Spencer mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets Blood 109 2007 1975 1983
132. F.M. Williams Clinical significance of esterases in man Clin Pharmacokinet 10 1985 392 403
133. S.E. Williams, C.N. Floyd, and M. Marber The changing face of acute coronary syndromes Heart Metab 50 2011 9 14
134. K.W. Woodhouse, H. Wynne, S. Baillie, O.F. James, and M.D. Rawlins Who are the frail elderly? Q J Med 68 1988 505 506
135. K.K. Wu, A.C. Papp, C.E. Manner, and E.R. Hall Interaction between lymphocytes and platelets in the synthesis of prostacyclin J Clin Invest 79 1987 1601 1606
136. M. Wurtz, E.L. Grove, S.D. Kristensen, and A.M. Hvas The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease Heart 96 2010 368 371
137. C. Yelland, J. Summerbell, E. Nicholson, B. Herd, H. Wynne, and K.W. Woodhouse The association of age with aspirin esterase activity in human liver Age Ageing 20 1991 16 18
138. N.D. Yeomans, Z. Tulassay, L. Juhasz, I. Racz, J.M. Howard, and C.J. van Rensburg A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group N Engl J Med 338 1998 719 726
139. X. Yi, Q. Zhou, J. Lin, L. Chi, and Z. Han Platelet response to aspirin in Chinese stroke patients is independent of genetic polymorphisms of COX-1 C50T and COX-2 G765C J Atheroscler Thromb 20 1 2013 65 72
140. N. Zimmermann, A. Wenk, U. Kim, P. Kienzle, A.A. Weber, and E. Gams Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery Circulation 108 2003 542 547
141. 2 Prostaglandins Leukot Essent Fatty Acids 56 1997 85 91